Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor

Amer Assal; Baoxia Dong; Hina Khan; Ramadevi Medavarapu; Aditi Shastri; Kith Pradhan; Ellen Friedman; Ioannis Mantzaris; Murali Janakiram; Ramakrishna Battini; Noah Kornblum; Yiting Yu; Amit K. Verma; Ira Braunschweig; Olga Derman

doi:10.3109/10428194.2016.1142087

Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor

Amer Assal, Baoxia Dong, Hina Khan, Ramadevi Medavarapu, Aditi Shastri, Kith Pradhan, Ellen Friedman, Ioannis Mantzaris, Murali Janakiram, Ramakrishna Battini, Noah Kornblum, Yiting Yu, Amit K. Verma, Ira Braunschweig, Olga Derman

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1-4
Number of pages	4
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.3109/10428194.2016.1142087
State	Accepted/In press - Feb 12 2016

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428194.2016.1142087

Cite this

Assal, A., Dong, B., Khan, H., Medavarapu, R., Shastri, A., Pradhan, K., Friedman, E., Mantzaris, I., Janakiram, M., Battini, R., Kornblum, N., Yu, Y., Verma, A. K., Braunschweig, I., & Derman, O. (Accepted/In press). Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. Leukemia and Lymphoma, 1-4. https://doi.org/10.3109/10428194.2016.1142087

Assal, A, Dong, B, Khan, H, Medavarapu, R, Shastri, A , Pradhan, K, Friedman, E, Mantzaris, I, Janakiram, M, Battini, R, Kornblum, N, Yu, Y, Verma, AK, Braunschweig, I & Derman, O 2016, 'Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor', Leukemia and Lymphoma, pp. 1-4. https://doi.org/10.3109/10428194.2016.1142087

@article{abdce1f81bdb42ccb5fc8ba6b0ca36e1,

title = "Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor",

author = "Amer Assal and Baoxia Dong and Hina Khan and Ramadevi Medavarapu and Aditi Shastri and Kith Pradhan and Ellen Friedman and Ioannis Mantzaris and Murali Janakiram and Ramakrishna Battini and Noah Kornblum and Yiting Yu and Verma, {Amit K.} and Ira Braunschweig and Olga Derman",

year = "2016",

month = feb,

day = "12",

doi = "10.3109/10428194.2016.1142087",

language = "English (US)",

pages = "1--4",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor

AU - Assal, Amer

AU - Dong, Baoxia

AU - Khan, Hina

AU - Medavarapu, Ramadevi

AU - Shastri, Aditi

AU - Pradhan, Kith

AU - Friedman, Ellen

AU - Mantzaris, Ioannis

AU - Janakiram, Murali

AU - Battini, Ramakrishna

AU - Kornblum, Noah

AU - Yu, Yiting

AU - Verma, Amit K.

AU - Braunschweig, Ira

AU - Derman, Olga

PY - 2016/2/12

Y1 - 2016/2/12

UR - http://www.scopus.com/inward/record.url?scp=84958521129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958521129&partnerID=8YFLogxK

U2 - 10.3109/10428194.2016.1142087

DO - 10.3109/10428194.2016.1142087

M3 - Article

C2 - 26886689

AN - SCOPUS:84958521129

SN - 1042-8194

SP - 1

EP - 4

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this